BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33186040)

  • 1. Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo.
    Guo J; Luo L; Wang Z; Hu N; Wang W; Xie F; Liang E; Yan X; Xiao J; Li S
    J Med Chem; 2020 Nov; 63(22):13825-13850. PubMed ID: 33186040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
    Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
    Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
    J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
    Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
    Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
    Cao H; Cheng B; Liu T; Chen J
    Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
    Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
    J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Evaluation of
    OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
    J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
    Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Qin M; Cao Q; Zheng S; Tian Y; Zhang H; Xie J; Xie H; Liu Y; Zhao Y; Gong P
    J Med Chem; 2019 May; 62(9):4703-4715. PubMed ID: 30964291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, Evaluation, and Structural Studies of
    Basu S; Yang J; Xu B; Magiera-Mularz K; Skalniak L; Musielak B; Kholodovych V; Holak TA; Hu L
    J Med Chem; 2019 Aug; 62(15):7250-7263. PubMed ID: 31298541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Qin M; Meng Y; Yang H; Liu L; Zhang H; Wang S; Liu C; Wu X; Wu D; Tian Y; Hou Y; Zhao Y; Liu Y; Xu C; Wang L
    J Med Chem; 2021 May; 64(9):5519-5534. PubMed ID: 33938739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
    Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
    J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
    Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
    Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.